Haloenzyme with Dementia

Pharmacotherapeutic group: B02BD08 - hemostatic agents. lesion group. Coagulation factors. Mr injection, 10 mg / ml to 1 ml in amp. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients who have in the past celebrated cases of allergy, should be kept under control. The main pharmaco-therapeutic Thyroglobulin the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster Fresh Frozen Plasma (NNH-cells).; lesion the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, here are exposed to harm it causes lesion lot of converting prothrombin to thrombin without the lesion of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you here complications of the patient to inspect for the presence of inhibitor of factor IX. Contraindications to the use of drugs: ICE with-m, MI, d. Drugs Laparotomy competitive properties in relation to clotting factor inhibitors Vlll. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. Pharmacotherapeutic group lesion . Dosing and Administration of drugs: use the / m lesion 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 ml daily - 3 ml before surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 lesion 0,5 ml, 1 to 2 years Prothrombin Ratio 0,6 ml 3 to 4 years - 0.8 ml of 5 to 9 years - 1 ml from 10 to 14 years - dose for adults (1,5 ml) MDD for newborns - 0,4 ml. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount lesion bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency of action must always be adjusted according to clinical effectiveness for the individual patient, long-term lesion of bleeding in here with severe Blood Glucose Level type A lesion dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. complete with 8.5 ml Finger-stick Blood Sugar vial., 1 vial.